APOE3

Researchers sequenced the APOE gene in over 900 individuals, finding supporting evidence for the APOE2 allele's role in longevity and lower levels of lipids.

The "opt-in" model ensures that customers are aware of the risks and limitations of this potentially sensitive data, but some are questioning whether the direct-to-consumer model is the appropriate mechanism for delivering information on APOE status, even with additional precautions.

Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.

Studies presented at an international conference this week suggest that TOMM40 genotyping could be a useful diagnostic strategy for predicting which healthy people with a family history of Alzheimer's will develop the disease early.

In a recent issue of The Pharmacogenomics Journal, a team led by Allen Roses, director of Duke University's Deane Drug Discovery Institute, published data from two independent study populations linking longer lengths of a polymorphic poly-T variant, rs10524523, with a higher risk of late-onset Alzheimer's disease. "This paper provides the data and the first opportunity for other research laboratories to test and validate the data," the study authors note.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.